A Phase 1 interventional study of LQT-1213 and Placebo in Long QT Syndrome, sponsored by Thryv Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-26.
Sponsored by Thryv Therapeutics, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.
Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 1, and was the 40th registered.
101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.
Browse Long QT Syndrome studies →7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:
Thryv Therapeutics, Inc. · Sites in United States
Ages 15+
Washington University School of Medicine · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 4 · Phase 3 2 · Phase 4 5
First in 1985; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 45 across 46 interventional studies indexed under Long QT Syndrome.
Median enrollment 44 across the 28 interventional studies, 96 across the 16 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 44 have an industry lead sponsor. The 10 most frequent:
Thryv Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Thryv Therapeutics, Inc. has 3 studies filed under Long QT Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Long QT Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277582Phase 3Thryv Therapeutics, Inc.Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) | 2027-06-30 |
| NCT04336644Washington University School of MedicineContinuous Versus Intermittent cARdiac Electrical moNitorinG | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Long QT Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
Key Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A, 4 dosing cohorts will receive a single oral dose of LQT-1213. The highest dose of LQT-1213 to be administered is 1.67 mg/kg.
Drug: LQT-1213
In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
Drug: LQT-1213
In Part B, 3 dosing cohorts will receive LQT-1213 in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
Drug: LQT-1213
In Part A, 6 dosing cohorts will receive a single oral dose of placebo.
Other: Placebo
In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
Other: Placebo
In Part B, 3 dosing cohorts will receive placebo in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
Other: Placebo
LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Matching Placebo
Safety and Tolerability: Number of Participants with Adverse Events
Number of Participants with Adverse Events
Time frame: Part A SAD: Day 7; Part A Food Effect: Day 15; Part B MAD: Day 16
Plasma Pharmacokinetics of LQT-1213: Tlag
Initial plasma concentration lag time
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8
Plasma Pharmacokinetics of LQT-1213: Cmax
Maximum observed plasma drug concentration
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1 and 7
Plasma Pharmacokinetics of LQT-1213: Tmax
Time to maximum observed plasma drug concentration
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1
Plasma Pharmacokinetics of LQT-1213: T1/2
Terminal phase half-life
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1 and 7
Plasma Pharmacokinetics of LQT-1213: AUC0-12, AUC0-T, and AUC0-∞=
Area under the plasma drug concentration versus time curve
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1
Plasma Pharmacokinetics of LQT-1213: CL/F
Clearance, parent only
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1
Plasma Pharmacokinetics of LQT-1213: Vz/F
Volume of distribution, parent only
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1
Plasma Pharmacokinetics of LQT-1213: λz
Terminal elimination rate constant
Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8
Urine Pharmacokinetics of LQT-1213: Ae
Amount of the administered dose recovered over the entire 24-hour interval
Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8
Urine Pharmacokinetics of LQT-1213: Ae0-t
Amount excreted unchanged in urine over a given time interval
Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8
Urine Pharmacokinetics of LQT-1213: Fe
Percentage of the administered dose recovered over the entire 24-hour interval
Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8
Urine Pharmacokinetics of LQT-1213: Fe/F
Fraction of dose excreted in urine
Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8
Urine Pharmacokinetics of LQT-1213: CLR
Renal clearance Ae0-t/AUC0-t
Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8
Plasma Pharmacokinetics of LQT-1213: Ctrough
Concentration of drug in the blood immediately before the next dose is administered
Time frame: Part B MAD: Days 3-6
Plasma Pharmacokinetics of LQT-1213: Cmin
Minimum observed plasma drug concentration
Time frame: Part B MAD: Day 7
Plasma Pharmacokinetics of LQT-1213: AUC0-tau, AUC0-T, and AUC0-∞
Area under the plasma drug concentration versus time curve
Time frame: Part B MAD: Day 7
Plasma Pharmacokinetics of LQT-1213: CL/Fss
Clearance, parent only
Time frame: Part B MAD: Day 7
Plasma Pharmacokinetics of LQT-1213: Vz/Fss
Volume of Distribution, parent only
Time frame: Part B MAD: Day 7
Plasma Pharmacokinetics of LQT-1213: Rac(AUC) and Rac(Cmax)
Drug accumulation ratio
Time frame: Part B MAD: Day 7
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Mar 2023, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thryv Therapeutics, Inc.